U.S. Food and Drug Administration Approval: Peginterferon-alfa-2b for the Adjuvant Treatment of Patients with Melanoma

On March 29, 2011, the U.S. Food and Drug Administration approved peginterferon alfa-2b (PEG-IFN) (Sylatron™; Schering Corporation, Kenilworth, NJ) for the adjuvant treatment of melanoma patients with microscopic or gross nodal involvement following definitive surgical resection including complete l...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Herndon, Thomas M., Demko, Suzanne G., Jiang, Xiaoping, He, Kun, Gootenberg, Joseph E., Cohen, Martin H., Keegan, Patricia, Pazdur, Richard
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2012
Assuntos:
Regulatory Issues: FDA
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3481898/
https://ncbi.nlm.nih.gov/pubmed/23002124
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0123
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados